Intention,
engineered into biology.
Ruyi Therapeutics is a research-stage biotechnology company building a structural discovery platform that turns difficult biological targets into tractable therapeutic programs.
A name built on intention
Ruyi Therapeutics, LLC is a biotechnology company engaging in research activities, headquartered in Westwood, Massachusetts. We operate at the discovery and preclinical stage, applying structural biology and computational chemistry to targets that have historically resisted conventional drug design.
Our teams work across oncology, immunology, and neuroscience, sharing a single internal platform for target validation, molecule generation, and iterative testing — built so that a lesson learned in one program compounds across the next.
Research-first
Every program begins from unresolved biology, not a licensing opportunity.
Structural rigor
Decisions are grounded in structural and mechanistic evidence before a program advances.
Deliberately small
A lean team, close to the bench, with short distance between question and experiment.
Three problems worth solving slowly
Each program pairs a validated biological target with a therapeutic modality suited to it. All programs described below are in discovery or preclinical stages and are not approved for use in humans.
Targeted Protein Degradation — Oncology
A bifunctional small-molecule series designed to selectively degrade a scaffolding protein implicated in treatment-resistant solid tumors.
Selective Modulation — Immunology
An orally available modulator of an inflammatory signaling node, developed to narrow immune activity without broad suppression.
RNA-Targeted Therapy — Neuroscience
Early-stage work exploring RNA-directed intervention in a genetically defined neurodegenerative pathway.
Internal Discovery Platform
Our shared infrastructure for structural modeling, molecule generation, and assay design — the throughline across every program above.
From structure to candidate
Target validation
Candidate targets are confirmed against structural and genetic evidence before any chemistry begins.
Structure-guided design
Molecule generation is informed directly by resolved or predicted structural models of the target.
Iterative testing
Rapid design–test–learn cycles narrow a wide chemical series down to a defensible lead.
Led from the bench
Liling Zeng
Liling Zeng serves as Manager of Ruyi Therapeutics, LLC, overseeing the company's research direction, operations, and its registered activities in the Commonwealth of Massachusetts.
Under this leadership, Ruyi Therapeutics maintains a research-driven structure: a small team, a shared discovery platform, and programs chosen for scientific merit rather than speed to market.
Registered & in good standing
Ruyi Therapeutics, LLC is organized under the laws of the State of Delaware and registered to conduct business in the Commonwealth of Massachusetts.
Reach the team
For research inquiries: we welcome contact from academic collaborators, contract research partners, and prospective team members.
Ruyi Therapeutics does not offer any product, service, or investigational therapy directly to patients. All programs listed on this site are in the research or preclinical stage.
For all other inquiries, please write to the email address above and a member of the team will respond within two business days.